Patient and observer reported outcome measures to evaluate health-related quality of life in inherited metabolic diseases: a scoping review

Carlota Pascoal, Sandra Brasil, Rita Francisco, Dorinda Marques-da-Silva, Agnes Rafalko, Jaak Jaeken, Paula A. Videira, Luísa Barros and Vanessa dos Reis Ferreira

Abstract

Background: Health-related Quality of Life (HrQoL) is a multidimensional measure, which has gained clinical and social relevance. Implementation of a patient-centred approach to both clinical research and care settings, has increased the recognition of patient and/or observer reported outcome measures (PROMs or ObsROMs) as informative and reliable tools for HrQoL assessment. Inherited Metabolic Diseases (IMDs) are a group of heterogeneous conditions with phenotypes ranging from mild to severe and mostly lacking effective therapies. Consequently, HrQoL evaluation is particularly relevant.

Objectives: We aimed to: (1) identify patient and/or caregiver-reported HrQoL instruments used among IMDs; (2) identify the main results of the application of each HrQoL tool and (3) evaluate the main limitations of HrQoL instruments and study design/methodology in IMDs.

Methods: A scoping review was conducted using methods outlined by Arksey and O'Malley. Additionally, we critically analysed each article to identify the HrQoL study drawbacks.

Results: Of the 1954 studies identified, 131 addressed HrQoL of IMDs patients using PROMs and/or ObsROMs, both in observational or interventional studies. In total, we identified 32 HrQoL instruments destined to self- or proxy-completion; only 2% were disease-specific. Multiple tools (both generic and disease-specific) proved to be responsive to changes in HrQoL; the SF-36 and PedsQL questionnaires were the most frequently used in the adult and pediatric populations, respectively. Furthermore, proxy data often demonstrated to be a reliable approach complementing self-reported HrQoL scores. Nevertheless, numerous limitations were identified especially due to the rarity of these conditions.

Conclusions: HrQoL is still not frequently assessed in IMDs. However, our results show successful examples of the use of patient-reported HrQoL instruments in this field. The importance of HrQoL measurement for clinical research and therapy development, incites to further research in HrQoL. PROMs’ and ObsROMs’ creation and validation in IMDs.

Keywords: Patient reported outcome measures (PROMs), Observer reported outcome measures (ObsROMs), Quality of life (QoL), Health-related quality of life (HrQoL), Inherited metabolic disease(s) (IMD(s))
Background
Rare diseases are usually characterized by striking heterogeneity and complexity associated with a lack of evidence-based data and access to clinical experts. This makes it difficult for patients and caregivers to guide their decisions about disease management [1]. These factors have a tremendous impact on patients’ health-related quality of life (HRQoL) [2]. HRQoL is defined as a multidimensional concept referring to the subjective evaluation of the impact of the health status in domains related to physical, mental, emotional, and social functioning. It goes beyond direct measures of population health, life expectancy, and causes of death [3]. Patient-centred care is a recent approach in research and clinical practice [4]. One of the ways in which this concept has been advanced is through the development of patient or observer reported outcome measures (PROMs or ObsROMs, respectively). PROMs are direct reports from patients regarding their health condition registered via validated questionnaires with robust psychometric properties [5]. ObsROMs are reports made by a proxy who is in direct contact with the patient when it is not possible to obtain self-reports [6].

PROMs have numerous applications in diverse settings, including research, policy decision-making or treatment effectiveness assessment [7–9]. Besides facilitating communication between patients and clinicians (which improves healthcare provision), they can also improve patient outcomes [10]. Importantly, the use of PROMs is highly supported by regulatory agencies, such as the European Medicine Agency (EMA) and the Food and Drug Administration (FDA) [5, 11]. They are frequently used in clinical trials, mainly as surrogate endpoints [12, 13]. Among other parameters and variables, PROMs can be used to evaluate HRQoL [13–15]. While PROMs and ObsROMs are often used in common chronic conditions [16, 17], these tools have not often been applied or even developed in rare diseases, due to their specificities [6, 18, 19]. However, there are a few examples of the successful use of PROMs in rare diseases, particularly in academia, by PROM methodologists, and in collaboration with patient organizations [6, 20].

There is a need for PROMs in rare inherited metabolic disorders (IMDs), a group of more than 1000 heterogeneous and often life-threatening diseases [21]. The introduction of newborn screening programs detecting currently more than 50 IMDs and the development of new therapies, increased survival, prevalence, and improved patient outcomes [22, 23]. However, living with an IMD affects the patients’ HRQoL due to the wide range of diverse and debilitating symptoms and their chronic restrictive diets [24]. Moreover, the natural history of many IMDs is not well defined. This hampers the establishment of care guidelines. Most importantly, a curative treatment is rarely available. Subsequently, patients are generally confronted with a low HRQoL. Without adequate PROMs it is difficult to robustly monitor both symptoms and therapies in IMDs.

PROMs that specifically assess HRQoL are a particularly relevant outcome in chronic and debilitating conditions, especially because biomarkers are not always associated with meaningful benefits to the patients [25]. Until 2013, fewer than 30% of clinical studies for orphan drugs included QoL-related outcomes [26]. We reviewed the literature with three aims: (1) to identify patient and/or caregiver-reported HRQoL instruments – both generic and disease-specific - used among IMDs (2) to identify the main results of the application of each HRQoL tool and (3) to evaluate the main limitations of HRQoL instruments and study design/methodology in IMDs to guide future studies.

Methods
Data source and search strategy
Our scoping review strategy followed the methodological framework outlined by Arksey and O’Malley [27]. We searched the PubMed database with pre-defined search terms from inception until 26th February 2018. No other sources were included because we are a non-profit organization without external funding and, consequently, no access to databases that require subscription. Two groups of search terms (Additional file 1) were employed: 1) QoL related and 2) IMDs related terms. Free text terms were generated through a pilot PubMed search. We applied every combination of search terms from both groups connected by the Boolean operator “AND”. Resulting articles from our search were exported to Mendeley Desktop and duplicated articles were eliminated. References of relevant articles were screened, and additional articles were included by author referral.

Study selection and data extraction
The review was conducted by two researchers. Inclusion criteria were as follows: studies had to be written in English and measure HRQoL using a PROM/ObsROM in an IMD context. Clinician reported outcomes, interviews and reviews were excluded, in order to focus on empirical research-generated evidence. Titles and abstracts were screened and studies that did not meet the criteria were excluded. The remaining article full-text versions were then read and included or excluded according to pre-defined criteria. Any disagreements were settled by discussion.

Critical appraisal strategy
The methodological quality of included studies was assessed using a checklist (Additional file 2) with criteria adapted from a published HRQoL assessment study [28]. The main limitations of the included studies were identified resorting to this checklist.

Results
The initial search of PubMed identified 1954 articles, 13 of which were duplicates. The title and abstract-based selection
excluded 1744 articles. One hundred ninety-seven studies moved to the second round of selection. Based on the full-text review of each article, 91 were excluded and 108 were included. Reference screening or author referral led to the inclusion of 23 additional articles. Finally, 131 articles met the inclusion criteria. These were published between 1999 and 2017. The selection workflow is presented in Fig. 1.

Generic and specific HrQoL instruments in IMDs pediatric and adult populations
In total, we identified 32 HrQoL assessment instruments used across IMDs (Table 1). While 84% of the manuscripts reported the use of only one HrQoL instrument, 13% applied two and another 3% used three or more instruments. The 36-Item Short Form Health Survey (SF-36) was the most frequently used measure to evaluate HrQoL across IMDs, applied in 53% of all included studies, followed by the EuroQoL Five Dimension (EQ-5D) questionnaire (17%). Concerning the pediatric population, the Pediatric Quality of Life Inventory (PedsQL) and the Child Health Questionnaire (CHQ) were found to be the most utilized either as self- or proxy-reports, present in 12 and 8% of the studies, respectively. Of note, the total number of instruments applied to the pediatric population is similar to that of the adult population (17 and 15 tools, respectively). However, the number of studies designed to assess HrQoL in adults is far superior to the ones directed to children. Only 2% of the studies resorted to specific instruments. Remarkably, only one of these tools is specific for adults, whereas three target children. Among the IMDs in which HrQoL was assessed, only phenylketonuria (PKU) has disease-specific questionnaires, however, there are still studies that use generic instruments to evaluate HrQoL in PKU patients. Importantly, among the identified tools there is a broader instrument targeting metabolic diseases, namely the Qol. Scale for Metabolic Diseases-Parent Form. This is a validated, author-built questionnaire specifically developed to evaluate the HrQoL of children with restrictive diets [24]. Despite clear efforts, only about 7% of the more than the 1000 identified IMDs have registered patient or observer-reported HrQoL assessments.

Proxy-reports to complement self-reports
Most metabolic disorders affect not only adults but also the pediatric population. Tools adjusted to obtain information on this population, such as PedsQL and CHQ, have been developed including proxy-versions. It is a common methodological assumption that self-reports are the best method for collecting information [29], because they are the vision of oneself. In contrast, proxy-reports tend to reflect the point of view of another. However, young age and/or disease impact raise the need for proxy-reports [6]. In fact, only 6% of the analysed manuscripts registered the sole use of proxy-reports [30–37].

A combined approach of both proxy- and self-reports to obtain HrQoL data was used in 21% of the studies. For 7% of the articles analysed, there were no differences between self- and parent-proxy data [30, 38–45]. Nevertheless, parent-reported HrQoL scores were lower than reports of children with Niemann-Pick disease, MPS VI, MSUD, other OAs and UCDs. [30, 46–51] Only in one case, in contrast, higher QoL regarding the fatigue scale was reported by parents of type II citrullinemia patients when compared with the self-reports [51].

HrQoL is generally impaired in IMDs
A rising number of studies using self- and/or proxy reported PROMs or ObsROMs to evaluate the impact of IMDs in HrQoL. has been registered. These include both observational studies and baseline measurements performed in interventional studies. The SF-36 questionnaire was the most frequently used (51% of the studies), particularly in the adult population. This instrument revealed overall HrQoL impairment in a wide range of IMDs, including Fabry disease [52–59], Gaucher disease type I [60, 61], Pompe disease [62–65], mevalonate kinase deficiency [66], hereditary hemochromatosis [67], acute porphyrias [68], MELAS [69], McArdle disease [70], MPS [35, 71], Niemann-Pick type B [47], Niemann-Pick type C [72] and X-linked hypophosphatemia [73]. The EQ-5D (15%) showed consistently low HrQoL scores in Fabry disease [52, 53, 74], Pompe disease [75], MPS [76, 77] and acute porphyrias [68]. Less frequently used tools, namely TAAQOL (6%), SF-12 (4%), PLC (4%), SIP-136 (one study) and WHOQOL-BREF (one
| Instrument Name | Sub-scales | Item number | Target Group (years) | IMDs |
|-----------------|------------|-------------|----------------------|------|
| **Adolescent- and adult-oriented instruments** | | | | |
| **General** | | | | |
| 15D | Mobility, vision, hearing, breathing, sleeping, eating, speech, excretion, usual activities, mental function, discomfort, depression, distress, vitality, sexual activity | 15 | > 16 | Familial hypercholesterolemia [95] |
| AQOL-4D | Independent living (self-care, household tasks and mobility), relationships (friendships, isolation and family role), mental health (sleeping, worrying and pain) and senses (seeing, hearing and communication) | 12 | 15–19 (norm) | Hereditary haemochromatosis [144] |
| EQ-SD | Mobility, self-care, usual activities, pain/discomfort, anxiety/depression | 5 plus the VAS | > 18 | Acute porphyrias [68], Fabry disease [52, 53, 88, 120–122, 127, 135, 154], hereditary hemochromatosis [155], Pompe Disease [75, 131], mucopolysaccharidosis (MPS) II [52] |
| EQ-SD-5 L | | 5 plus the VAS | | MPS Iva [76, 90] |
| EQ-SD-3 L | | 5 plus the VAS | | Fabry disease [74], MPS [146], MPS II [77] |
| EQ-5 VAS | | 1 | | Fabry disease [129, 156], Wilson disease [157] |
| NHP | Energy level, pain, emotional reaction, sleep, social isolation, physical abilities, work, house tasks, social functioning, sex life, interests and hobbies, vacations. | 45 | > 16 | Pompe disease [119] |
| PGWBI | Anxiety, depression, positive well-being, self-control, general health, vitality | 22 | > 18 | PKU [133] |
| PLC | Emotional, practical and social impact, disease-specific symptoms, diet and therapeutic impact | 40 | Adolescents and adults | Galactosemia [79], PKU [93] |
| SIP-136 | Sleep and rest, eating, work, home management, recreation and pastimes, ambulation, mobility, body care and movement, social interaction, alertness behavior, emotional behavior, communication | 136 | Adolescents, adults and elderly | MELAS [69] |
| SIP-68 | Somatic autonomy, mobility control, mobility range, social behaviour, emotional stability, psychological autonomy/communication | 68 | Adolescents, adults and elderly | Niemann-Pick disease type C [72] |
| SF-36 | Physical functioning, role limitations due to physical health, body pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. | 36 | > 14 | Acute porphyrias [68], carnitine palmitoyltransferase II deficiency [158], cystinuria [143], Fabry disease [52–57, 87, 92, 107–111, 132, 141, 145, 147, 159–162], familial hypercholesterolemia [95, 112], Gaucher disease [60, 61, 98, 99, 113, 114, 128, 163, 164], GSD type I [117], hereditary hemochromatosis [67, 155, 165], mevalonate kinase deficiency [66], McArdle disease [70, 100, 101], MELAS [69], MPS [35], MPS IV [71, 115], Niemann-Pick type B [47] and type C [72], PKU [89, 94, 166], Pompe disease [62–65, 102–105, 118, 167–169], Wilson disease [116, 140, 170], X-linked hypophosphatemia [73] |
| SF-36-6D | Physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. | 11 | | Pompe disease [131] |
| SF-12 | Physical functioning, role limitations, social functioning, pain, mental health, vitality | 12 | > 12 | Familial hypercholesterolemia [91], hypophosphatasia [80], LC-FAOD [38] |
| TAAQOL | Gross motor functioning, fine motor functioning, cognition, sleep, pain, social contacts, daily activities, sex, vitality, happiness, depressive mood, anger | 45 | > 16 | Galactosemia [89], mevalonate kinase deficiency [66], PKU [46, 94] |
| Instrument Name | Sub-scales | Item number | Target Group (years) | IMDs |
|-----------------|------------|-------------|----------------------|------|
| WHOQOL-100      | Vitality, psychological well-being, relationship with friends, leisure activities, relationship with parents, physical well-being, relationship with teachers, school, body image, relationship with medical staff. | 100 | > 18 | IMDs [125], PKU [43] |
| WHOQOL-BREF     | Physical health, psychological health, social relationships, and environment | 26 | > 18 | Pompe disease [126], OAs, including MMA, PA, IVA and GA1; and UCDs, including CPS1 deficiency, citrullinemia type I, ASL deficiency, HHH syndrome and OTC deficiency [50], oculocutaneous albinism [81], Wilson disease [171] |

Specific

| Instrument Name | Sub-scales | Item number | Target Group (years) | IMDs |
|-----------------|------------|-------------|----------------------|------|
| PKU-QOL Adult version | PKU symptoms, PKU in general (emotional, practical, social and overall impact), administration of Phe-free protein supplements, dietary protein restriction | 65 | > 18 | PKU [89] |

Pediatric instruments

General

| Instrument Name | Sub-scales | Item number | Target Group (years) | IMDs |
|-----------------|------------|-------------|----------------------|------|
| CHQ             | General health, physical functioning, role limitations due to emotional problems, role limitations due to physical health, body pain, behaviour, global behaviour, mental health, self-esteem, general health perceptions, emotional parental impact, time parental impact, family activities, family cohesion. | 87 | 5–18 | Familial hypomagnesemia [85], MPS IH [36], MPS II [37] |
| CHQ-CF87        | Sensation, mobility, emotion, cognition, self-care, pain, fertility | 28 | 5–18 | Fabry disease [82], MPS II [42] |
| CHQ-PF28        | Vision, hearing, speech, ambulation, dexterity, emotion, cognition, pain | 50 | 5–18 | Fabry disease [40, 82], MPS II [42], Niemann-Pick type B [47], PKU [166] |
| CHQ-PF50        | Independence, emotion, inclusion, exclusion, limitations, treatment | 37 | Children and adolescents with chronic diseases | PKU [46] |
| DISABKIDS-37    | Walking/standing, Reach/grip, Sleeping, School/work, Activities and Breathing; and a satisfaction-with-function and a botheredness-with-function domains | 15 (self) | > 5 | Fabry disease [40] |
| HUI 2           | | 15 (self) | > 5 | Fabry disease [40], MPS II [42] |
| HUI 3           | | 27 | 8–18 | MPS II [77] |
| KIDSCREEN-27    | Physical well-being, psychological well-being, autonomy and parents, peers & social support, school environment | 4–16 | PKU [44, 45], carbohydrate metabolism disorders including GSD, galactosaemia, and fructose-1,6-bisphosphatase deficiency; OAs including MMA, PA, MSUD, 3-methylcrotonyl CoA carboxylase deficiency and 3-hydroxy-2-methylglutaryl CoA lyase deficiency; and amino acid metabolism disorders including PKU, alkaptonuria, homocystinuria and tyrosinemia [24] |
| KINDL           | | 12: self 46: proxy | 4–6 or their parents | Propionic acidemia [37] |
| KiddyKINDL      | | 24 | 7–13 or their parents | PKU [43, 46, 50, 84, 89], OAs, including MMA, PA, IVA, GA1, UCDs, including CPS1 deficiency, citrullinemia type I, ASL deficiency, HHH syndrome and OTC deficiency [50], citrin deficiency [51], MPS [35], GSD type I [39], MSUD [48], nephopathic cystinosis [123], Fabry disease [83] |
| KidKINDL        | | 24 | 14–17 or their parents | |
| KiddokKINDL     | | 23 | 5–18 | |
Table 1  HrQoL instruments used across IMDs as PROMs or ObsROMs (Continued)

| Instrument Name | Sub-scales | Item number | Target Group (years) | IMDs |
|----------------|------------|-------------|----------------------|------|
| PedsQOL parent version | Upper extremity function, transfers and mobility, physical function and sports, comfort (lack of pain), happiness, satisfaction, and expectations | 23 | Parents of 2–18 years old patients | MPS Na [115] |
| SF-10 | Physical functioning, role-physical, bodily pain, general health perceptions, vitality, social functioning, role emotional and mental health | 10 | 5–18 children’s parents | LC-FAOD [38] |
| TACQOL | General physical functioning, motor functioning, autonomy, cognition, social contacts, positive mood, negative mood | 56 | 6–11 or their parents (parent form) | Cystinosis [86], familial hypercholesterolemia [96], galactosemia [89], PKU [30], MPS VI [49] |
| TAPQOL | Stomach problems, skin problems, lung problems, sleeping problems, appetite, problem behaviour, positive mood, anxiety, liveliness, social functioning*, motor functioning* and communication* | 43 | Parents of 9-months-6 years children | Galactosemia [89] MPS VI [49] |
| VSP-Ae | Gross motor functioning, fine motor functioning, cognition, sleep, pain, social contacts, daily activities, sex, vitality, happiness, depressive mood, anger | 38 | 8–10 | OAs, UCDs, MSUD [41] |
| VSP-A | Physical functioning, motor functioning, autonomy, cognitive functioning, social functioning, positive and negative emotional functioning | 39 | 11–17 | OAs, UCDs, MSUD [41] |
| VSP-Ap | Symptoms, sleeping, appetite, motor functioning, behaviour, social functioning, communication, positive and negative emotional functioning | 37 | Parents of patients of all ages | OAs, UCDs, MSUD [41] |

Specific

| PKU-QOL Child | PKU symptoms, PKU in general (emotional, practical, social and overall impact), administration of Phe-free protein supplements, dietary protein restriction | 40 | 9–11 | PKU [89] |
| PKU-QOL Parent | PKU patients’ parents | 58 | 12–17 | |
| PKU-QOLQ | Impact, worries, satisfaction, support, well-being | NA | 10–18 | PKU [124] |
| QoL Scale for Metabolic Diseases – Parent Form | Impact of disease, attention, perception of disease, physical function, stigmatization, social support, school status, and health perception | 28 | Parents of children (1–15) with a metabolic disorder treated with restrictive diet for at least 1 year | Carbohydrate metabolism disorders, including GSD, galactosemia, fructose-1,6-bisphosphatase deficiency; OA including MVA, PA, MPS, 3–methylcrotonyl CoA carboxylase deficiency, 3-hydroxy-2-methylglutaryl CoA lyase deficiency; amino acid metabolism disorders including PKU, alkaptonuria, homocystinuria, tyrosinemia [24] |

HrQoL tools were divided into 2 main categories: adult-oriented and pediatric instruments. They were then further classified into general and disease-specific tools. Abbreviations: AQOL-4D Assessment of Quality of Life 4D, ASL Argininosuccinate lyase, CHQ Child Health Questionnaire, CPS1 Carbamylphosphate synthase synthase 1, GAA Glutaric aciduria type I, GSD Glycogen storage disease, HHH Hyperammonemia-hyperomithinemia-homocitrullinuria, HUH Health Utilities Index, MELAS Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episode, LC-FAOD Long-chain fatty acid oxidation disorders, MAA Methylmalonic acidemia, IVA Isovaleric acidemia, MPS Mucopolysaccharidosis, MSUD Maple syrup urine disease, NHP Nottingham Health Profile, OAs Organic acidurias, OTC Ornithine transcarbamylase, PA Propionic acidemia, PedsQOL Pediatric Quality of Life inventory, PGWB Psychological General Well-Being Index, PLC Profile for the Chronically ill, PKU-QOL Phenylketonuria-Quality of Life, SIP Sickness Impact Profile, SF-36 36-item Short Form survey, TAAQOL TNO-AZL questionnaire for adult’s HrQoL, TACQOL TNO-AZL questionnaire for children’s HrQoL, TAPQOL TNO-AZL questionnaire for preschool children’s HrQoL, UCDS Urea cycle disorders, VAS Visual analogue scale, VSP-A Vécu et Santé pour l’Adolescent, WHOQOL World Health Organization Quality of Life

*Only for children older than 18 months
study), detected reduced HRQoL in galactosemia (only at the mental level) [78, 79], hypophosphatasia [80], MELAS [69] and oculocutaneous albinism (only at the physical level) [81].

Regarding instruments applied to the pediatric population, the PedsQL and the CHQ were administered in 11 and 9% of the studies, respectively. They described compromised HRQoL in Fabry disease [82, 83], MPS [35, 37, 42], PKU [84], Niemann-Pick type B [47], familial hypomagnesemia [85], MSUD [48], methylmalonic acidemia [34] and GSD type I [39]. The TACQOL (8%) and TAPQOL (4%) detected low HRQoL in cystinosis [86], galactosemia [78], MPS VI [49] and PKU (only at the emotional level) [30]. Two other tools were administered in MPS II, in one study each, namely the HUI 3 and KIDSCREEN-27, revealing a negative impact of this disease on HRQoL [42, 77].

The detrimental effect of IMDs on patients’ HRQoL is mainly attributed to disease severity and associated complications, but also to its emotional and financial burden. We found several parameters and comorbidities associated with impaired HRQoL, namely, age, kidney and respiratory function, pain, overweight, the burden of a restrictive diet as well as gastrointestinal, cardiovascular, skeletal and neurologic involvement [52, 57, 58, 60, 61, 63, 74, 76–79, 87–92].

In a set of cases, the employment of HRQoL instruments did not show substantial impairments compared to control populations. Specifically, the administration of SF-36, PLC, TAAQOL, WHOQOL-100 and KINDL (the last used in 4% of the studies) found normal HRQoL scores in PKU patients [30, 43, 45, 93, 94]. Also, in familial hypercholesterolemia patients, SF-12, TACQOL and 15D (applied in one study) did not show differences in HRQoL compared to healthy peers [91, 95, 96]. No differences in HRQoL were found in patients with mevalonate kinase deficiency when the cognition scale of TAAQOL was administered alone. Importantly, KINDL application in propionic acidemia revealed normal HRQoL scores despite poor neurological and psychosocial outcomes [97].

**HRQoL tools detect changes upon treatment in IMD**

Besides clinical parameters and disease-specific biomarkers, HRQoL is now recognized as an essential instrument to determine therapeutic effects. Multiple studies included the assessment of changes in HRQoL upon treatment initiation to better evaluate the therapeutic benefits (Table 2). The SF-36 was predominantly utilized (67% of the interventional studies). Generally, this tool was capable of detecting alterations in HRQoL scores across several IMDs [60, 64, 98–114], with the exception of MPS IV and Wilson disease [115, 116]. Interestingly, whilst no changes were observed using SF-36 in late-onset Pompe disease, NHP was responsive in this patient niche [117–119].

Regarding EQ-5D, detectable variations were observed in Fabry disease patients [120–122]. However, HUI and CHQ administration in Fabry disease children did not perceive deviations in HRQoL [40]. Changes in HRQoL were captured by SF-12 in LC-FAOD. On the other hand, in this pediatric population, administration of parent-reported SF-10 did not reveal any differences [38]. In MPS IV, PODCI only detected differences in 1 out of 4 children [115]. PedsQL was able to find fluctuations in HRQoL of Fabry disease and nephropathic cystinosis patients [83, 123]. In MPS VI, the application of TAPQOL/TACQOL also detected modifications in HRQoL [49]. When HRQoL was measured using general instruments, namely TAAQOL, KINDL and PedsQL in PKU, BH₄ responsive patients’ HRQoL did not differ from non-responsive ones 24 months after treatment initiation [44, 46]. In contrast, HRQoL assessment with the specific PKU-QOLQ instrument detected a significant improvement in the responsive patients’ life quality for up to 1 year [124].

Attesting the importance of HRQoL PROMs and ObsROMs instruments, the continuous increase of HRQoL assessment reports in IMDs is accompanied by an increase in the number of approved therapies for these disorders (Fig. 2).

**Critical appraisal and main limitations of HRQoL studies**

We critically assessed the quality of the included studies and identified some concerns due to an increased risk of bias (see Additional file 2). Although most studies used a standardized generic tool, validation is rarely obtained for the population in which the instrument is being used. Therefore, the results of the use of a non-specifically validated tool for a certain population should be interpreted with caution. Mostly, the problems faced by clinical researchers dealing with IMDs are inherent to the rarity of these conditions. The biggest limitation is the small sample size [34, 37, 41, 53, 56, 65, 77, 82, 85, 100, 102, 105, 112, 115, 125–130]. This makes it difficult to reach statistically significant conclusions [35, 39, 43, 44, 46, 75, 79, 83, 86, 90, 93, 99, 131–133] and also precludes the use of adequate control samples as placebo-control groups [40, 58, 70, 76, 103, 108, 109, 119, 121, 134, 135]. To counteract the problem of small samples, multinational studies are being performed. However, this can raise other limitations, particularly cross-cultural differences [42, 70, 89] as well as variations in the range of investigations, protocol and rigor between centres [92, 121]. Still, pooling data from multinational studies might be adequate if the study design, the methods, linguistic and cognitive equivalence of the concepts being measured are achieved [136]. Thus, validation should be a never-ending process and one should always look for the psychometric and cross-cultural validity, reliability and acceptability of the measure in the context of each study. Nevertheless, small sample sizes might be considered representative due to the rarity of the condition and the study objectives [39, 52, 55, 78, 89, 95]. Some countries may not have normative data available and comparison of results with foreign data or with other chronic conditions may be a source of bias [52, 54, 70, 83, 128, 131]. Moreover, 55% manuscripts do not justify the selection of the HRQoL
| IMD | Sample (age in years) | Treatment/Therapy | Follow up time | HrQoL tool | Effects on HrQoL and major findings | Ref. |
|-----|-----------------------|-------------------|---------------|------------|------------------------------------|-----|
| Carnitine palmitoyl transferase II deficiency | Adults | Bezafibrate | 6 months | SF-36 | ↑ HrQoL in all domains, specialty role limitations due to physical health and body pain | [158] |
|  | Children and adults (10–55) | Anaplerotic diet therapy | 7–61 months | SF-36 | ↑ HrQoL in the physical component score | [106] |
| Fabry disease | Male adults (16–48) | Agalsidase-β | 10 days-20 weeks | SF-36 | Phase 1/2 trial that proved the efficiency and safety of Fabrazyme including an ↑ HrQoL, namely regarding bodily pain, general health, vitality, physical role and emotional role domains. Placebo effects were noticed. | [107, 108] |
|  | Adults and adolescents (> 14) | Agalsidase-β | 3 years | SF-36 | ↑ HrQoL more pronounced in men | [109] |
|  | Adults (41.4, mean) | Agalsidase-β | 2 years | SF-36 | Ns changes in HrQoL | [110] |
|  | Male adults (16–34) | Agalsidase-β | 20 weeks | SF-36 | ↑ HrQoL with significant changes in the general health and the mental component score | [107, 108] |
|  | Adults | Agalsidase-α | 2 years | EQ-5D | Significant ↑ HrQoL | [111] |
|  | Adults | Agalsidase-α | 2 years | EQ-5D | Significant ↑ HrQoL which negatively correlates with pain | [112] |
|  | Adults (39.2 ± 12.3, mean) | Agalsidase-α | 5 years | EuroQoL | Significant ↑ HrQoL | [113] |
|  | Adults (males: 44.25 ± 11; females: 52.3 ± 10.5, means) | Agalsidase-α | 4 weeks | EQ-5D | Ns differences in HrQoL in the 3 dose regimens. (NCT01218659) | [120] |
|  | Heterozygous females (20–66) | Agalsidase-α | 55 weeks | SF-36 | Phase 3 study that proved the agalsidase-α safety and efficacy in heterozygous females with significant ↑ HrQoL, mostly in the physical domain. | [114] |
|  | Children (7–18) | Agalsidase-α | 55 weeks | HUI, CHQ | Phase 2 study that showed the efficiency and safety of agalsidase-α, however HrQoL remained unchanged. (NCT01363492) | [115] |
|  | Adults (42.5 ± 12.5, mean) | ERT | 6.1 ± 2.5 years | EQ-SD | ↑ HrQoL in severely affected males | [116] |
|  | Adults (26–68) | ERT | 4–7 years | SF-36 | Unchanged HrQoL in women | [117] |
|  | Children (6–18) | ERT | – | PedsQL | Stable HrQoL except for the social functioning score. | [118] |
|  | Adults (16–74) | Migalastat | 2 years | SF-36 | Children on ERT had higher scores that approached significance. | [119] |
| Familial hypercholesterolemia | Children and adults (9–57) | LDL apheresis | NA | SF-36 | Results did not reveal any clinical benefit (NCT00925301 and NCT01458119) | [120] |
| Gaucher disease type I | Children and adults (12–70) | Imiglucerase | 4 years | SF-36 | Significant ↑ HrQoL in the physical component score and, particularly, the physical functioning, physical role limitations and bodily pain subscores. (NCT00365131) | [121] |
|  | Adults (18–82) | Imiglucerase | 2 years | SF-36 | Since baseline HrQoL approached those of the general population, there was no space for improvements and ns changes were observed. | [122] |
|  | Adults (17–69) | Miglustat | 6–24 months | SF-36 | Miglustat administration significantly ↑ HrQoL, while imiglucerase or combination of both reduced HrQoL | [123] |
|  | Adults (35.2 ± 10.2, mean at start) | Miglustat | 12–48 months | SF-36 | Similar improvements in HrQoL between miglustat and ERT-treated patients. | [124] |
|  | Adults (18–66) | ERT | 2 years | SF-36 | Self-perception of global health, physical activity and social functioning improved with ERT. | [125] |
|  | Children and adults (> 5) | ERT or SRT | 10 years (mean) | SF-36 | 65 patients achieved the therapeutic goal for HrQoL but differences between treated and untreated patients were ns. | [126] |
Table 2 PROMs/ObsROMs HrQoL instruments used across IMDs to evaluate therapeutic benefit in clinical studies (Continued)

| IMD                        | Sample (age in years)                                                                 | Treatment/Therapy | Follow up time | HrQoL tool | Effects on HrQoL and major findings                                                                                           | Ref. |
|----------------------------|--------------------------------------------------------------------------------------|-------------------|----------------|------------|--------------------------------------------------------------------------------------------------------------------------------|------|
| Children and adults (> 12) (one type 3 Gaucher disease patient) |                                                                              | ERT               | 8.5 years (mean) | SF-36      | - Bodily pain was significantly decreased in ERT-naive patients but physical functioning, role physical, general health, social functioning and role emotional scores showed clinical meaningful impairments too.  
- Gaucher disease patients receiving ERT have significant higher scores than Fabry disease patients also receiving ERT. | [128] |
| Hereditary hemochromatosis | Adults (55 ± 9.0, mean)                                                             | Erythrocytapheresis | 2 years        | SF-36      | - There is no benefit in terms of HrQoL of erythrocytapheresis over phlebotomy. (NCT01398644)                                   | [155] |
| MPS IH                     | Children and adults (2–25)                                                          | Hematopoietic cell transplant | 9 years (mean) | CHQ-PF50   | - Higher age at transplant correlates with poor physical scores                                                            | [36]  |
| LC-FAOD                    | Children and adults (12.06 ± 13.2, mean)                                           | Triheptanoin (UX007) | 24 weeks       | SF-12, SF-10 | - Significant ↑ HrQoL in the physical and mental domains for adults but not for children. (NCT01886378)                        | [38]  |
| MPS VI                     | Children and adults (5–21)                                                          | Arylsulfatase B    | 1.3–5–4 years  | TAPQOL, TACQOL | - ↑ HrQoL regarding lung problems, sleeping, liveliness, positive mood, social functioning and communication  
- ↓ HrQoL in the anxiety and negative emotions domains                                                                            | [49]  |
| McArdle’s disease          | Adults (18–60)                                                                      | Ramipril           | 3 months       | SF-36      | - ↑ HrQoL in the emotional status and social role in both ramipril and placebo groups                                     | [100, 101] |
| MPS IV                     | Children and adults (9.8–42.2)                                                      | Elosulfase-α       | 48–96 weeks    | SF-36, PODCI | - Stable HrQoL, except in 1 child with ↓ HrQoL (NCT01697319)                                                                 | [115] |
| Nephropathic cystinosis    | Children and adolescents (6–21)                                                     | Delayed-release cysteamine bitrate | 2 years       | PedsQL     | - Significant ↑ HrQoL particularly in social, school and total function.                                                   | [123] |
| Pompe disease              | Adults (41–42)                                                                      | Alglucosidase-α    | 2 years        | SF-36      | - ↑ HrQoL, particularly in the bodily pain domain                                                                           | [102] |
| Adults (28–62)             | Alglucosidase-α                                                                      | 52 weeks          | SF-36          |            | - 3/5 patients improved both physical and mental scores while 1/5 improved only the mental or the physical score           | [103] |
| Late onset adults (27–73)  | Alglucosidase-α                                                                      | 36 months         | SF-36          |            | - Ns differences from baseline                                                                                               | [117] |
| Late onset adults (21–69)  | Alglucosidase-α                                                                      | 1 year            | SF-36          |            | - Ns differences from baseline                                                                                               | [118] |
| Adults (24–76, at start)   | ERT                                                                                  | 4 years (median)  | SF-36          |            | - Significant ↑ HrQoL in the physical functioning, role physical, general health, vitality and mental health subscores, after 2 years. After 4 years, the bodily pain domain significantly worsened. | [64]  |
| Adult (65)                 | L-alanine                                                                            | 6 months          | SF-36          |            | - ↓ HrQoL, mainly the physical domain due to worsening of muscle function. ↑ HrQoL during placebo interval reflecting the optimism of entering a trial. | [104] |
| Adults (20–71)             | Exercise program                                                                     | 12 weeks          | SF-36          |            | - Borderline ↑ HrQoL at the mental component                                                                                   | [105] |
| Late onset adults (35.5–60.7) | Inspiratory muscle training program                                                  | 8 weeks           | NHP            |            | - Significant ↑ HrQoL exclusively in the social isolation subscore                                                             | [119] |
| PKU                        | Children and adults (4–44)                                                          | BH4               | 1 year         | PedsQL, TAAQOL | - Unchanged HrQoL and similar between responsive and non-responsive patients                                                    | [46]  |
| Children and adolescents (6.6–18.7) | BH4                                   | 6 months          | KINDL          |            | - Unchanged HrQoL and similar between responsive and non-responsive patients                                                    | [44]  |
| Children and adults (10–49) | BH4                                   | 1 year            | PKU-QOLQ       |            | - ↑ HrQoL in responders, provisional responders and non-responders in terms of impact, satisfaction                       | [124] |
instrument used. Since a variety of general instruments are available, this selection process should be clearly defined. Additionally, some answer option systems might not be capable of detecting small changes in health (i.e. EQ-5D) [74].

Some HrQoL studies are performed to assess the effects of a certain therapy. Consequently, they are administered before and after the therapy to provide baseline data and to register any possible improvement, respectively. In these cases, loss to follow-up due to noncompliance or abandonment is a recurrent issue [46]. Furthermore, missing data decreases the statistical validity/power of the study. Imputation of missing values can be made by researchers, but this is not always possible [137]. Finally, unreported clinical history and/or genotype data impair possible correlations with HrQoL scores [83].

Disease heterogeneity is very common to IMDs [31, 40, 75, 89, 99, 103, 115]. On the one hand, in cross-sectional studies severe forms of a disease can counterbalance the higher HrQoL scores reached by patients with less severe presentations and vice-versa [43, 61, 71, 87, 138]. On the other hand, in order to avoid erroneous conclusions drawn from differently affected patient samples, careful individual inclusion and sampling should be performed [42]. In line with this, longitudinal designs are a better approach to establish the natural history of the disease, pinpoint predictive factors of impaired HrQoL as well as to identify pre

### Table 2 PROMs/ObsROMs HrQoL instruments used across IMDs to evaluate therapeutic benefit in clinical studies (Continued)

| IMD                  | Sample (age in years) | Treatment/Therapy | Follow up time | HrQoL tool | Effects on HrQoL and major findings |
|----------------------|-----------------------|-------------------|---------------|------------|-----------------------------------|
| Wilson disease       | Children and adults (8–41) | Orthotopic liver transplantation | 97 months (mean) | SF-36 | Ns difference between norm-based scores and patients who underwent transplantation [116] |
| Adults (36.6 ± 12.9) | D-penicillamine, trientine, zinc | 8.1–12.6 years (mean) | SF-36 | D-penicillamine-treated patients had the highest HrQoL scores compared to trientine- or zinc-treated patients [140] |

Abbreviations: AQOL-4D Assessment of Quality of Life 4D, CHQ Child Health Questionnaire, HUI Health Utilities Index, LDL Low-density lipoprotein, NA non available, NHP Nottingham Health Profile, Ns No significant, PedsQL Pediatric Quality of Life Inventory, PGWBI Psychological General Well-Being Index, PLC Profile for the Chronically Ill, PODCI Pediatric Outcomes Data Collection Instrument, PKU-QOL Phenylketonuria-Quality of Life, SF-36 36-Item Short Form Survey, TAAQOL TNO-AZL questionnaire for Adult’s HrQoL, TACQOL TNO-AZL Questionnaire for Children’s HrQoL, TAPQOL TNOAZL Questionnaire for Preschool Children’s HrQoL, VSP-A Vécu et Santé Percue de l’Adolescent, WHOQOL World Health Organization Quality of Life

---

**Fig. 2** HrQoL assessment studies VS approved therapies in IMDs; Legend: Graph showing the number of HrQoL assessment studies (light blue) and approved therapies (dark blue) for the IMDs included in this review over time. The number of approved therapies is based on a specific search including EMA (http://www.ema.europa.eu), FDA (https://www.fda.gov) and Clinical Trials.gov (https://clinicaltrials.gov)
and community support. The inclusion of patients with either severe or milder forms of the disease (convenience sampling) can cause a shift towards advocacy groups, health care institutions and patient registries represented.

Observation of changes in HrQoL over time can be difficult due to ceiling effects (i.e. patients with scores near the upper scale limit have less room for improvement) [109, 124]. In this case, high HrQoL values have been proposed to be due to (i) the disability paradox, e.g., disabled individuals reporting good HrQoL because they focus on their coping strategies and positive emotions [46, 50, 116]; (ii) patients’ expectations adaptation throughout their illness experience; (iii) adaptation by repeatedly using the same instrument [74] and (iv) variation of symptom severity [53]. Importantly, studies focusing on adult patients may often underestimate the overall disease impact on HrQoL since severely affected patients may die during infancy. The spectrum of disease severity is thus not fully represented [80].

Selection bias may arise from recruitment through patient advocacy groups, health care institutions and patient registries (convenience sampling) [142]. This can cause a shift towards the inclusion of patients with either severe or milder forms of a disease who can be more or less likely to seek medical care and community support [54, 57–59, 64, 73, 76, 78, 80, 82, 92, 93, 96, 99, 143–146]. Volunteer participation and the patient-reported character of the questionnaires may indirectly exclude patients with poor literacy or cognition [79]. Further inherent drawbacks to patient-reported data include non-verification of diagnosis and symptomatology in medical records [31, 58, 63, 80, 143, 144, 146], recall bias [31, 34, 70, 147] and social desirability [70].

Discussion

Nowadays, regulatory agencies such as FDA, EMA or health technology assessment bodies are turning to HrQoL. PROMs data to support decision making. However, PROMs are not yet used routinely in clinical practice. These tools can provide natural history data, but also clinical endpoints for therapeutic trials. Consequently, there is a rise of HrQoL assessment studies using PROMs or ObsROMs in rare IMDs to fill in this gap. This reinforces the importance and need for these instruments to accelerate research and effective clinical solutions.

We identified 32 instruments used either to assess patients’ HrQoL or to evaluate the risk or benefit of a specific treatment. Most of the instruments found are generic since for most IMDs, specific instruments are still inexistent. The predominant use of SF-36 is probably due to its validity in an extensive group of populations, languages, and the fact that it comprises a wide age range (14 years and older) [148]. The second most used tool was the EQ-5D, mainly within adult populations. Recently, the EuroQoL group developed the EQ-5D-Y, the child-friendly version of EQ-5D, which might increase the use of this instrument. However, until today, no population norms using EQ-5D-Y have been published. There are considerable fewer studies focused on assessing HrQoL in children. The lack of natural history studies in this population, the perception of a better health, the inability to respond for themselves, and the fact that there are many less pediatric clinical trials might be contributing factors. Nevertheless, the PedsQL and the CHQ were used in 12 and 8% of the studies respectively. The fact that these instruments can be used either as PROMs and/or ObsROMs might contribute to their frequent use compared to other pediatric tools. Frequently, studies with a combined approach of self- and proxy-reports are carried out in this population. This is even more common in disorders presenting cognitive developmental disability. Also important is the reduced ability of young children to identify issues in emotional functioning [83]. Proxy reports can accurately reflect the same aspects as observed in patients. However, they can also reflect the parent’s state of mind, fears and doubts regarding their children, which results in lower HrQoL scores [46]. Therefore, self and proxy HrQoL data should be acquired and compared.

Due to the great symptom heterogeneity found among IMDs, we cannot however grade the 32 instruments found accordingly to their appropriateness to use in these disorders. Therefore, the research team should always look for the conceptual design of each instrument and analyse if it is suitable for the features of the patient population under assessment.

Generic instruments present some advantages. They can be applied to every disease or clinical manifestation and allow comparisons between different patient groups or between patients and healthy populations. However, they are not directed to the features of each condition. This may omit meaningful clinical outcomes limiting the study power [36, 46, 47, 50, 62, 64, 77, 147]. Disease-specific instruments include relevant questions related to a particular disease and thus are more responsive and sensitive [149]. However, they only confer the capability of making comparisons within the same patient group. Only two studies applied disease-specific tools, namely PKU-QOL and PKU-QOLQ [89, 124]. This fact further highlights the lack of specific HrQoL PROMs in the field of IMDs. As disease-specific and generic instruments assess different aspects of HrQoL, the use of both instruments in a complementary way has been suggested [150, 151]. A new group of HrQoL instruments is arising, namely disease group-specific instruments. In the metabolic field, we identified the QoL scale for Metabolic Diseases-Parent Form. More recently, a new promising but still not validated tool was developed for pediatric patients with intoxication type inherited errors of metabolism [152]. These tools focus on common aspects of different diseases, thus allowing comparisons across related but distinct patient populations. Furthermore, they are particularly important in rare diseases since they can overcome limitations associated with small sample size.

We identified instruments capable of detecting changes in HrQoL compared to normative data or following
treatment/therapy initiation while others were not responsive. Additionally, in the case of Fabry adult patients, the results of the administration of SF-36 in three different studies evaluating the same therapeutic intervention diverged [109, 110, 141]. Thus, conclusions should be drawn with caution since other variables besides the quality of the intervention may influence the results. In fact, study design, sampling methods, suitability of the HrQoL instrument for a specific population and its selection according to the study characteristics are important factors to consider in order to obtain robust and reliable results. Additionally, the illness burden in several IMDs is not always easy to prove. For example, in propionic acidemia patients, no significant changes in HrQoL were found in comparison with normal individuals in spite of their poor neurocognitive and psychosocial outcomes [97]. However, we cannot exclude the fact that some IMDs affect patient’s HrQoL to a lesser degree. This has been observed in PKU [30, 43, 45, 93, 94] and familial hypercholesterolemia [91, 95, 96] after efficient treatment following early diagnosis. Nevertheless, although existing tools are not responsive in these subgroups, the measurement of the impact of a highly restrictive diet on patients’ QoL is extremely relevant and needed. In fact, PROMs are being developed on this topic to correctly evaluate the HrQoL of these patients [24].

Promising strategies to develop specific HrQoL PROMs that efficiently capture the patient’s perspective, prognosis, impactful clinical manifestations and that establish the natural history of the disease include:

- qualitative interviews with patients, their families and caregivers;
- patient registries, which also motivate patient enrollment in research projects and clinical trials [10]. The fact that Fabry disease is the condition with higher HrQoL assessment, is likely to be a direct consequence of the successful establishment of two patient registries - the Fabry Outcome Survey (NCT03289065) and the Fabry Registry (NCT00196742). Both include periodic HrQoL evaluations as a clinical outcome;
- clinical trials networks that facilitate data sharing and collaborations, ultimately improving access to the available information [153].

**Conclusion and future directions**

Patient-centred approaches based on patients’ HrQoL are expanding by the implementation of PROMs or ObsROMs in clinical practice and research settings. However, this review makes it clear that they are still poorly utilized in the field of IMDs. There is a huge gap in the development of responsive disease-specific HrQoL measurement instruments that could be useful endpoints in clinical trials. To overcome the limitations inherent to the rarity of these conditions, efforts should be made not only to develop but also to adequately validate these tools. The successful establishment of international patient registry platforms might be the path with biggest potential to upgrade HrQoL studies across IMDs. They facilitate patient recruitment and uniform data collection worldwide. In line with this, the European Commission health program included a project that consists in a novel registry platform for all known IMDs – the Unified European Registry for Inherited Metabolic Disorders (https://u-imd.org/). Although there is still a long way to go as far as the proper implementation of patient-centred care is concerned, these studies and instruments are important efforts in the right direction. HrQoL assessment through PROMs and ObsROMs are an efficient way of prioritizing the patient perspective. They drive research and more rapidly create therapeutic solutions that meet the patients’ needs and expectations.

**Additional files**

**Additional file 1:** Search methodology: List of the terms used to search the Pubmed database and search strategy. (DOCX 18 kb)

**Additional file 2:** Article critical appraisal: 19 items checklist for the critical appraisal of the included studies. (DOCX 71 kb)

**Abbreviations**

- HrQoL: (Health-related) quality of life; CHQ: Child Health Questionnaire; EMA: European Medicine Agency; EQ-5(3)D: EuroQol five(three)-dimension; FDA: Food and Drug Administration; IMD(s): Inherited metabolic disorder(s); P(Obs)RO(M/s): Patient (observer) reported outcomes (measure/s); PedsQL: Pediatric Quality of Life Inventory; PKU: Phenylketonuria; SF-36: 36-Item Short form health survey

**Acknowledgements**

C.P. and S.B. acknowledge CDG&Allies-PPAIN for the 5th and 6th Liliana Scientific Initiation Scholarship, respectively. R.F. acknowledges Fundação para a Ciência e Tecnologia with the grant SFRH/BD/124326/2016 awarded to her. We also thank Prof. Liz Forbat and the members of the CDG & Allies – Professionals and Patient Associations International Network (CDG & Allies-PPAIN), whose network expertise greatly helped in the creation of this manuscript.

**Funding**

This work was supported by the 5th and 6th Liliana Scientific Initiation Fellowships from CDG & Allies - Professionals and Patient Associations International Network (CDG&Allies-PPAIN) awarded to C.P. and S.B., respectively. R.F. was funded by Fundação para a Ciência e Tecnologia with the grant SFRH/BD/124326/2016 awarded to her.

**Availability of data and materials**

All data generated or analysed during this study are included in this published article [and its supplementary information files].

**Authors’ contributions**

VRF and LB developed the concept and design of this study. CP and SB performed all the search methodology, results analysis and the writing of this manuscript. RF contributed to the result analysis, writing and to the revision of the manuscript. LB, JJ, PV, AR and DMS critically revised the manuscript for important intellectual content. All authors gave final approval of the version to be published.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.
Competing interests
V.R.F. is the president and founder of the Portuguese Association for Congenital Disorders of Glycosylation. A.R. is the president of GlycomeInc. The costs regarding this publication were covered by GlycomeInc. All other authors declare no conflict of interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Portuguese Association for Congenital Disorders of Glycosylation (CDG), Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal. 2CDG & Allies - Professionals and Patient Associations International Network (PPAIN), Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal. 3Research Unit on Applied Molecular Biosciences (UCIBIO), Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Lisbon, Portugal. 4GlycomeInc, Inc, 953 Indiana St, San Francisco, CA 94107, USA. Center for Metabolic Diseases, UZ and KU Leuven, Leuven, Belgium. 5Faculdade de Psicologia, Universidade de Lisboa, 1649-013 Lisbon, Portugal.

Received: 15 August 2018 Accepted: 14 November 2018
Published online: 28 November 2018

References
1. Bonnier N, Abetz-Webb L, Renault L, Caballero T, Longhurst H, Maurer M, et al. Development and content validity testing of a patient-reported outcomes questionnaire for the assessment of hereditary angioedema in observational studies. Health Qual Life Outcomes. 2015;13:1–15.
2. Bogart KR, Irvin VL. Health-related quality of life among adults with diverse rare disorders. Orphanet J Rare Dis. 2017;12:177.
3. Healthy People 2020. Health-Related Quality of Life and Well-Being. 2010.
4. Robbins DA, Curro FA, Fox CH. Defining patient-centricity: opportunities, challenges, and implications for clinical care and research. Ther Innov Regul Sci. 2013;47:349–55.
5. FDA. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims Clinical/Medical Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Health Qual Life Outcomes. 2006;4:79. https://doi.org/10.1186/1477-7525-4-79.
6. Basch E, Bennett A V. Patient-reported outcomes in clinical trials of rare diseases. J Gen Intern Med. 2014;29:249–53.
7. Bevan M, Ross A, Cella D. Patient-reported outcomes measurement information system (PROMS): efficient, standardized tools to measure self-reported health and quality of life. Nurs Outlook. 2014;62:339–45.
8. Brennahan BW, Rundell SD. Including patient-reported outcomes and patient-reported resource-use questionnaires in studies. Acad Radiol. 2014; 21:1129–37.
9. Kyte DG, Calvert M, van der Wees PJ, ten Hove R, Tolan S, Hill JC. An introduction to patient-reported outcome measures (PRQMs) in physiotherapy. Physiother (United Kingdom). 2015;101:119–25.
10. Slade A, Isa F, Kyte D, Parkhurst T, Kerecuk L, Ferguson J, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13:1–9.
11. EMEA. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQoL) measures in the evaluation of medicinal products. 2005.
12. Dinan M, Compton K, Dhillon J. Use of patient-reported outcomes in randomised, double-blind, placebo-controlled clinical trials. Med Care. 2014;50:491–9.
13. Brandage M, Bass B, Davidson J, Queenan J, Beigak A, Ringash J, et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res. 2011;20:653–64.
14. Winkl M, Compton A. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life. Fundam Clin Pharmacol. 2004;18:351–63.
15. Zeltner NA, Huemer M, Baumgartner MR, Landolt MA. Quality of life, psychological adjustment, and adaptive functioning of patients with intoxication-type inborn errors of metabolism - a systematic review. Orphanet J Rare Dis. 2014;13:159.
16. Ridgeway JL, Beebe TJ, Chute CG, Eton DT, Hart LA, Frost MH, et al. A brief patient-reported outcomes quality of life (PROQL) instrument to improve patient care. PLoS Med. 2013;10:e1001548.
17. Nelson EC, Efthimiou E, Lind C, Hager A, Wasson JH, Lindblad S. Patient reported outcome measures in practice. BMJ. 2015;350:f10 14g7818.
18. Khangura SD, Karacepe MO, Trakadas Y, Mitchell JJ, Chaikarobaty P, Tingley K, et al. Scoping review of patient- and family-oriented measures and guidelines for chronic pediatric disease. BMC Pediatr. 2015;15:17.
19. Johnston BC, Miller PA, Agarwal A, Mulla S, Khokhar R, De Oliveira K, et al. Limited responsiveness related to the minimal important difference of patient-reported outcomes in rare diseases. J Clin Epidemiol. 2016;79:10–21.
20. Ventovsek S, Mesa RA, Gottlib J, Levy RS, Gupta V, DelPiero JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:797–809.
21. Mak CM, Lee H-Ch, Chan AY-W, Lam C-W. Inborn errors of metabolism and expanded newborn screening: review and update. Crit Rev Clin Lab Sci. 2013;50:142–62.
22. Bennett MJ. Newborn screening for metabolic diseases: saving children’s lives and improving outcomes. Clin Biochem. 2014;47:699–4.
23. Matern D, Rinaldo P. Newborn Screening for Inherited Metabolic Disease. In: Inherited Metabolic Diseases, Berlin, Heidelberg: Springer Berlin Heidelberg; 2017. p. 421–437.
24. Eminoglu TF, Soysal SA, Turner L, Okur I, Hasanoglu A. Quality of life in children treated with restrictive diet for inherited metabolic disease. Pediatr Int. 2013;55:428–33.
25. Huang ME, Warrella JE, Kreutzer JS. Functional outcomes and quality of life in patients with brain tumors: a preliminary report. Arch Phys Med Rehabil. 2001;82:1540–6.
26. Picavet E, Casirain D, Holak CE, Maetens JA, Simoens S. Clinical evidence for orphan medicinal products-a cause for concern? Orphanet J Rare Dis. 2013;8:164.
27. Arkesy H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19–32.
28. Picot J, Copley V, Colquitt JL, Kalika N, Hartwell D, Bryant J. The INTRABEAM® photon radiotherapy system for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation. Health Technol Assess (Rockv). 2015;19:1–190.
29. Mathiowetz NA, Groves RM. The effects of responder rules on health survey reports. Am J Public Health. 1985;75:639–44.
30. Landolt MA, Nuoffer J-M, Steinmann B, Superti-Furga A. Quality of life and psychologic adjustment in children and adolescents with early treated phenylketonuria can be normal. J Pediatr. 2002;140:515–21.
31. Calone J, Adams H, Augustine EF, Marshall FJ, Kwon JM, Newhouse N, et al. Females experience a more severe disease course in batten disease. J Inherit Metab Dis. 2012;35:549–55.
32. Ceravolo F, Mascaro I, Sestito S, Pascale E, Lauricella A, Dizione E, et al. Home treatment in paediatric patients with hunter syndrome: the first Italian experience. Ital J Pediatr. 2013;39:53.
33. Eggink H, Kuiper A, Peall KJ, Contario MF, Bosch AM, Post B, et al. Rare inborn errors of metabolism with movement disorders: a case study to evaluate the impact upon quality of life and adaptive functioning. Orphanet J Rare Dis. 2014;19:177.
34. Splinter K, Niemi AK, Cox R, Matt J, Shah M, Enns GM, et al. Impaired health-related quality of life in children and families affected by Methylmalonic Acidemia. J Genet Couns. 2016;25:936–46.
35. Kunin-Batson AS, Shapiro EG, Rudser KD, Lavery CA, Bjoraker KJ, Jones SA, et al. Long-term cognitive and functional outcomes in children with mucopolysaccharidosis (MPS)-IH (hurler syndrome) treated with UX007 for the treatment of long chain-fatty acid oxidation disorders: safety and efficacy in children and adults following 24weeks of treatment. Mol Genet Metab. 2017;120:370–7.
36. Storch E, Keesley M, Merlo L, Jacob M, Correia C, Weinstein D. Psychosocial functioning in youth with glycogen storage disease type I. Pediatr Psychol. 2008;33:728–38.
40. Goker-Alpan O, Longo N, McDonald M, Shankar SP, Schiffmann R, Chang P, et al. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naive to enzyme replacement therapy. Drug Des Devel Ther. 2016;10:771–81.

41. Fabre A, Baumstarck K, Cano A, Lourdou A, Berbis J, Chabrol B, et al. Assessment of quality of life of the children and parents affected by inborn errors of metabolism with restricted diet: preliminary results of a cross-sectional study. Health Qual Life Outcomes. 2013;11:158. https://doi.org/10.1186/1477-7525-11-158.

42. Raluy-Callado M, Chen W-H, Whiteman DAH, Fang J, Wiklund I. The impact of hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life. Orphanet J Rare Dis. 2013;8:101.

43. Cazorla C, Cegolon L, Burlina AP, Celato A, Massa P, Giordano L, et al. Quality of life (QoL) assessment in a cohort of patients with phenylketonuria. BMC Public Health. 2014;14:243.

44. Feldmann R, Volkert E, Weglage J, Rutsch F. Sapropterin treatment does not enhance the health-related quality of life of patients with phenylketonuria and their parents. Acta Paediatr. 2017;106:953–9.

45. Thimm E, Schmidt LE, Heltle K, Speikerhoetter U. Health-related quality of life in children and adolescents with phenylketonuria: unimpaired HRQoL in patients but feared school failure in parents. J Inherit Metab Dis. 2013;36:676–72.

46. Demirdas S, Maurice-Stam H, Boelen CCA, Hofstede FC, Janssen MCH, Langendonk JG, et al. Evaluation of quality of life in PKU before and after introducing tetrahydrobiopterin (BH4); a prospective multi-center cohort study. Mol Genet Metab. 2013;110:Suppl1:S94–S96.

47. McGovern MM, Mayserotten MF, Gugliani R, Bembi B, Vanier MT, Mengel E, et al. A prospective, cross-sectional survey of the natural history of Niemann-Pick disease type B. Pediatrics. 2008;122:e341–49.

48. Packman W, Henderson SL, Mehta I, Ronen R, Danner D, Chesterman B, et al. Assessment of quality of life of the children and parents affected by type 1 Gaucher disease: Spanish experience. Qual Life Res. 2005;14:453–62.

49. Brands MMMG, Oussoren E, Ruijter GJG, Vollebregt AAM, van den Hout WP, et al. Assessment of quality of life in inborn errors of metabolism with restricted diet: preliminary results of a cross-sectional study. Health Qual Life Outcomes. 2013;11:158.

50. McPherson GJ, Atkinson JC, Vigilant L, Schimenti J, Judge DP. A family-based study on health-related quality of life in patients with the m.3243A>G mutation and its correlations with genetic characteristics and disease manifestation. Orphanet J Rare Dis. 2016;11:25.

51. Meiser B, Dunn S, Dixon J, Powell LW. Psychological adjustment and knowledge about hereditary hemochromatosis in a clinic-based sample: a prospective study. J Genet Couns. 2005;14:453–63.

52. Millward LM, Kelly P, Deacon A, Senior V, Peters TJ. Self-rated psychosocial consequences and quality of life in the acute porphyrias. J Inherit Metab Dis. 2001;24:733–47.

53. Verhaak C, de Laat P, Koene S, Tiboobsch R, de Groot I, et al. Quality of life, fatigue and mental health in patients with the m.3243A>G mutation and its correlates with genetic characteristics and disease manifestation. Orphanet J Rare Dis. 2016;11:121.

54. Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry. Pediatr Res. 2008;64:550–552.

55. Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry. Mol Genet Metab. 2013;109:809–11.

56. Owusu-Edusei K, Ebben KG, Piekarz RL, Graber JL, et al. Health-related quality of life in males with Anderson Fabry disease before supportive care. J Inherit Metab Dis. 2011;34:1045–52.

57. Hendriksz CJ, Lavery C, Coker M, Ucar SK, Jain M, Bell L, et al. Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey. Orphanet J Rare Dis. 2014;9:32.

58. Guffon N, Heron B, Chabrol B, Feilet F, Montauban V, Valayannopoulos V. Diagnosis, quality of life, and treatment of patients with Morquio syndrome: a review of the French healthcare system: a retrospective observational study. Orphanet J Rare Dis. 2015;10:43.

59. Bosch AM, Grootenhuis MA, Bakker HD, Heijmans HSA, Wilburg FA, Last BF. Living with classical Galactosemia: health-related quality of life consequences. Pediatrics. 2004;113:e423–28.

60. Hoffmann B, Dragoano N, Schweitzer-Krantz S. Living situation, occupation and health-related quality of life in adult patients with classic galactosemia. J Inherit Metab Dis. 2012;35:1051–8.

61. Webers T, Wyatt EK, Moseley S, Oddie T, Khan N, et al. Health-related quality of life among people with porphyria: results from two patient-reported surveys. Metabolism. 2016;65:1522–30.

62. Maia M, Volpini BMF, dos Santos GA, Ruijala MJ. Quality of life in patients with ocuolucetal albinism. Ann Bras Dermatol. 2015;90:513–7.

63. Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, et al. Pediatric Fabry disease. Pediatrics. 2005;115:e444–55.

64. Boserus N, Naynor PE, Hudson K, Askó CD, Cordova MJ, Packman W. The psychosocial impact of Fabry disease on pediatriic patients. J Pediatr Genet. 2016;5:141–9.

65. Neto EV, Maio Filho HS, Monteiro CB, Carvalho LM, Tonon T, Vanz AP, et al. Quality of life and adherence to treatment in early-treated Brazilian phenylketonuric pediatric patients. Brazilian J Med Biol Res. 2017;51:e6709.
85. Guran T, Amman A, Alcay T, Kayan E, Atay Z, Turan S, et al. Cognitive and psychosocial development in children with familial hypomagnesaemia. Magnes Res. 2011;24:7–12.

86. Ullmer FF, Landolt MA, Ha Vinh R, Huisman TAGM, Neuhaus TJ, Latal B, et al. Intellectual and motor performance, quality of life and psychosocial adjustment in children with cystinosis. Pediatr Nephrol. 2009;24:1371–8.

87. Wagner M, Kramer J, Blohm E, Vergho D, Weidemann F, Breunig F, et al. Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease. BMC Nephrol. 2014;15:188.

88. Hoffmann B, Keshav S. Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr. 2007;96:984–6.

89. Bosch AM, Burlina A, Cunningham A, Bettolli E, Moreau-Stuckel F, Koledova E, et al. Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries. Orphanet J Rare Dis. 2015;10:80.

90. Lampe C, Jain M, Olaye A, Decker C, Mengel E. Relationship between patient-reported outcomes and clinical outcomes in patients with Morquio syndrome. J Inborn Errors Metab Screen. 2015;3:232640081567518.

91. Mata N, Alonso R, Baraness J, Zambrin D, Brea A, Mata P. Quality of life in a cohort of familial hypercholesterolaemia patients from the south of Europe. Eur J Pub Health. 2012;22:221–5.

92. Wyatt K, Henley W, Anderson L, Anderson R, Nikolaou V, Stein K, et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess. 2012;16:1–543.

93. Simon E, Schwarz M, Roos I, Dragano N, Képès F, Siegrist J, et al. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual Life Outcomes. 2008;6:25.

94. Bosch AM, Tybout W, van Spreuwen JF, de Valk HW, Wijburg FA, Grootenhuis MA. The course of life and quality of life and of early and continuously treated Dutch patients with phenylketonuria. J Inherit Metab Dis. 2007;30:29–34.

95. Hýttinen L, Nikkäläinen P, Vuorio AF, Sintonen H, Strandberg TE. Health-related quality of life in elderly patients with familial hypercholesterolaemia. Int J Technol Assess Health Care. 2008;24:228–34.

96. de Jongh S, Kerkhoffs MG, Grootenhuis MA, Bakker HD, Heymans RSA, Last BF. Quality of life, anxiety and concerns among stain-treated children with familial hypercholesterolaemia and their parents. Acta Paediatr. 2003;92:1096–101.

97. Grunert SC, Mullerleile S, De Silika L, Barth M, Walter M, Walter K, et al. Propionic academia: clinical course and outcome in 55 pediatric and adolescent patients. Orphanet J Rare Dis. 2013;8:66.

98. Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, et al. The impact of elosulfase alfa in patients with morquio a syndrome who have limited ambulation: an open-label, phase 2 study. Am J Med Genet A. 2017;173:375–83.

99. Sutcliffe RP, Maguire DD, Muespan E, Dhawan A, Miell-Vergani G, O’Grady JG, et al. Liver transplantation for Wilson’s disease: long-term results and quality-of-life assessment. Transplantation. 2003;75:1003–6.

100. Regner C, Kornblum C, Hansch F, Velhaber S, Strigli-Pill N, Grunert S, et al. 36 months observational clinical study of 38 adult Pompe disease patients treated with agalsidase beta enzyme replacement therapy. J Inherit Metab Dis. 2015;28:837–45.

101. Muth S, Klockgether T, Jänicke A. Progress of quality of life and health-related quality of life in patients with Fabry disease. Eur J Neurol. 2010;17:766.

102. Langman CB, Greenbaum LA, Grimm P, Sarwal M, Naudet P, Deschenes G, et al. Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrate. J Pediatr. 2014;165:528–33.e1.

103. Oktolovski D, Pellegrini N, Nigen H, Laffert P, Clarier R, Carlier P, et al. Recombinant human acid alpha-glucosidase (rGAA) in adult patients with severe respiratory failure due to Pompe disease. Neuro musculoskelet Disord. 2012;11:350–7.

104. Körtner H, Grady JG, Böhm N, Grime T, Kopp J, Mattiasson A, et al. Quality of life in patients with Gaucher disease: overall effects of agalsidase alfa treatment. J Inherit Metab Dis. 2014;37:52,rightmargin=24.

105. Mehta A, Beck M, Elliott P, Alfonso P, Curran P, Parvataneni K, et al. Effect of enzyme replacement therapy on pain and health related quality of life of patients with Fabry disease: data from or combination with intravenous enzyme replacement. Blood. 2007;10:112996–301.

106. Böhm N, Grady JG, Böhm N, Grime T, Kopp J, Mattiasson A, et al. Quality of life in patients with Gaucher disease: overall effects of agalsidase alfa treatment. J Inherit Metab Dis. 2014;37:52, rightmargin=24.

107. Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, et al. The impact of elosulfase alfa in patients with morquio a syndrome who have limited ambulation: an open-label, phase 2 study. Am J Med Genet A. 2017;173:375–83.

108. Fawzye MW, van den Berg LM, Kruishake MA, Wens SC, Prat SFE, Pim Pijnappel WWM, et al. Exercise training in adults with Pompe disease: the effects on pain, fatigue, and functioning. Arch Phys Med Rehabil. 2015;96:867–72.

109. Roe CR, Morley C. Apoptotic diet therapy in inherited metabolic disease: therapeutic potential. J Inherit Metab Dis. 2006;29:332–40.

110. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry’s disease. N Engl J Med. 2001;345:59–66.

111. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet. 2001;68:711–22.

112. Watt T, Burlina AP, Cazzorla C, Schonfeld D, Banikazemi M, Hopkin RJ, et al. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry registry. Genet Med. 2012;14:703–12.

113. Eto Y, Ohashi T, Utsunomyia Y, Fujimura M, Mizuno A, Inui K, et al. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. J Inherit Metab Dis. 2005;28:575–83.

114. Baehner F, Kampmann C, Whybra C, Miebach E, Wiedhoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIb study. J Inherit Metab Dis. 2003;26:617–21.

115. Graedel A, Bogrudi MP, Holven KS, Nenester MS, Nenverud I, Langset G, et al. Apheresis in homozygous familial hypercholesterolaemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolaemia. J Clin Lipidol. 2012;6:331–9.

116. Elstein D, Dieck W, Attias D, Hadas-Halpein I, Zevin S, Altarasuc E, et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood. 2007;10:112996–301.

117. Giraldo P, Alfonso P, Atutxa K, Fernandez-Galan MA, Berez A, Franco R, et al. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. Haematologica. 2009;94:1771–5.

118. Hatzmatt PR, Mengel E, Geberthov R, Muschol N, Hendrikz CJ, Burton BK, et al. Impact of elosulfase alfa in patients with morquio a syndrome who have limited ambulation: an open-label, phase 2 study. Am J Med Genet A. 2017;173:375–83.
